Fig. 1
From: Targeting the epigenome to reinvigorate T cells for cancer immunotherapy
Therapeutic targeting of the epigenetic regulators with specific and multi-target small molecule inhibitors. *as part of the polycomb repressive complex 2 (PRC2) epigenetic complex; ‘+’ indicates inhibitor-enzyme selectivity, and for EMCs with multiple substrates their highest selectivity is listed. PRMTs protein arginine methyltransferases, HKMTs histone lysine methyltransferases, HAT histone acetyltransferase, BETs bromodomain and extra-terminal domains, EZH1 enhancer of zeste homolog 1, EZH2 enhancer of zeste homolog 2, METTL3 methyltransferase like-3, BRD bromodomain-containing protein, KDMs lysine demethylases